Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells

Marie Therese Fuzzati-Armentero, Cristina Ghezzi, Robert Nisticò, Adriano Oda, Fabio Blandini

Research output: Contribution to journalArticle

Abstract

In the past decades, the clinical use of dopamine agonists has expanded from adjunct therapy in patients with a deteriorating response to l-3,4-dihydroxyphenylalanine (l-DOPA) to monotherapy for the treatment of early PD. Dopamine agonists provide their antiparkinsonian benefit through stimulation of brain postsynaptic type 2 dopamine receptors that exert their effect through classical cAMP-dependent mechanisms, as well as cAMP-independent cellular signaling cascades, including the Akt/glycogen synthase kinase 3 (GSK3) pathway. Alterations of Akt/GSK3 have been observed and may contribute to the neurodegenerative processes and the development of l-DOPA-induced dyskinesia. The effects l-DOPA and quinpirole, a dopamine agonist, on the two key regulatory kinases, Akt and GSK3, were evaluated in neuroblastoma cell line. l-DOPA and dopamine agonist dose-dependently and differentially modulated Akt and GSK3 expression and phosphorylation when added alone or combined. The combined treatment inverted or potentiated the modulatory properties of the single compound. The drug- and concentration-dependent balance of dopamine receptor stimulation over auto-oxidation may distinctively modulate GSK3 isoforms and Akt. Our results indicate that particular attention must be given to drug concentration and combination when multiple therapies are applied for the clinical treatment of PD patients.

Original languageEnglish
Pages (from-to)168-173
Number of pages6
JournalNeuroscience Letters
Volume552
DOIs
Publication statusPublished - 2013

Fingerprint

Quinpirole
Glycogen Synthase Kinase 3
Dihydroxyphenylalanine
Neuroblastoma
Dopamine Agonists
Phosphotransferases
Phosphorylation
Dopamine Receptors
Antiparkinson Agents
Therapeutics
Dyskinesias
Drug Combinations
Protein Isoforms
Cell Line
Brain
Pharmaceutical Preparations

Keywords

  • Akt
  • Dopamine agonists
  • GSK3
  • Neurodegeneration
  • Parkinson's disease
  • SH-SY5Y cells

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells. / Fuzzati-Armentero, Marie Therese; Ghezzi, Cristina; Nisticò, Robert; Oda, Adriano; Blandini, Fabio.

In: Neuroscience Letters, Vol. 552, 2013, p. 168-173.

Research output: Contribution to journalArticle

@article{6c1ca635b87442ab94a3b000d665cbb8,
title = "Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells",
abstract = "In the past decades, the clinical use of dopamine agonists has expanded from adjunct therapy in patients with a deteriorating response to l-3,4-dihydroxyphenylalanine (l-DOPA) to monotherapy for the treatment of early PD. Dopamine agonists provide their antiparkinsonian benefit through stimulation of brain postsynaptic type 2 dopamine receptors that exert their effect through classical cAMP-dependent mechanisms, as well as cAMP-independent cellular signaling cascades, including the Akt/glycogen synthase kinase 3 (GSK3) pathway. Alterations of Akt/GSK3 have been observed and may contribute to the neurodegenerative processes and the development of l-DOPA-induced dyskinesia. The effects l-DOPA and quinpirole, a dopamine agonist, on the two key regulatory kinases, Akt and GSK3, were evaluated in neuroblastoma cell line. l-DOPA and dopamine agonist dose-dependently and differentially modulated Akt and GSK3 expression and phosphorylation when added alone or combined. The combined treatment inverted or potentiated the modulatory properties of the single compound. The drug- and concentration-dependent balance of dopamine receptor stimulation over auto-oxidation may distinctively modulate GSK3 isoforms and Akt. Our results indicate that particular attention must be given to drug concentration and combination when multiple therapies are applied for the clinical treatment of PD patients.",
keywords = "Akt, Dopamine agonists, GSK3, Neurodegeneration, Parkinson's disease, SH-SY5Y cells",
author = "Fuzzati-Armentero, {Marie Therese} and Cristina Ghezzi and Robert Nistic{\`o} and Adriano Oda and Fabio Blandini",
year = "2013",
doi = "10.1016/j.neulet.2013.07.023",
language = "English",
volume = "552",
pages = "168--173",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells

AU - Fuzzati-Armentero, Marie Therese

AU - Ghezzi, Cristina

AU - Nisticò, Robert

AU - Oda, Adriano

AU - Blandini, Fabio

PY - 2013

Y1 - 2013

N2 - In the past decades, the clinical use of dopamine agonists has expanded from adjunct therapy in patients with a deteriorating response to l-3,4-dihydroxyphenylalanine (l-DOPA) to monotherapy for the treatment of early PD. Dopamine agonists provide their antiparkinsonian benefit through stimulation of brain postsynaptic type 2 dopamine receptors that exert their effect through classical cAMP-dependent mechanisms, as well as cAMP-independent cellular signaling cascades, including the Akt/glycogen synthase kinase 3 (GSK3) pathway. Alterations of Akt/GSK3 have been observed and may contribute to the neurodegenerative processes and the development of l-DOPA-induced dyskinesia. The effects l-DOPA and quinpirole, a dopamine agonist, on the two key regulatory kinases, Akt and GSK3, were evaluated in neuroblastoma cell line. l-DOPA and dopamine agonist dose-dependently and differentially modulated Akt and GSK3 expression and phosphorylation when added alone or combined. The combined treatment inverted or potentiated the modulatory properties of the single compound. The drug- and concentration-dependent balance of dopamine receptor stimulation over auto-oxidation may distinctively modulate GSK3 isoforms and Akt. Our results indicate that particular attention must be given to drug concentration and combination when multiple therapies are applied for the clinical treatment of PD patients.

AB - In the past decades, the clinical use of dopamine agonists has expanded from adjunct therapy in patients with a deteriorating response to l-3,4-dihydroxyphenylalanine (l-DOPA) to monotherapy for the treatment of early PD. Dopamine agonists provide their antiparkinsonian benefit through stimulation of brain postsynaptic type 2 dopamine receptors that exert their effect through classical cAMP-dependent mechanisms, as well as cAMP-independent cellular signaling cascades, including the Akt/glycogen synthase kinase 3 (GSK3) pathway. Alterations of Akt/GSK3 have been observed and may contribute to the neurodegenerative processes and the development of l-DOPA-induced dyskinesia. The effects l-DOPA and quinpirole, a dopamine agonist, on the two key regulatory kinases, Akt and GSK3, were evaluated in neuroblastoma cell line. l-DOPA and dopamine agonist dose-dependently and differentially modulated Akt and GSK3 expression and phosphorylation when added alone or combined. The combined treatment inverted or potentiated the modulatory properties of the single compound. The drug- and concentration-dependent balance of dopamine receptor stimulation over auto-oxidation may distinctively modulate GSK3 isoforms and Akt. Our results indicate that particular attention must be given to drug concentration and combination when multiple therapies are applied for the clinical treatment of PD patients.

KW - Akt

KW - Dopamine agonists

KW - GSK3

KW - Neurodegeneration

KW - Parkinson's disease

KW - SH-SY5Y cells

UR - http://www.scopus.com/inward/record.url?scp=84884300351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884300351&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2013.07.023

DO - 10.1016/j.neulet.2013.07.023

M3 - Article

VL - 552

SP - 168

EP - 173

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -